VX-121 is a CFTR corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.
A phase 2 study to test the safety and effectiveness of VX-121 is currently underway. This study is testing VX-121 in combination with another CFTR corrector, tezacaftor, and the CFTR potentiator VX-561.
This program is sponsored by Vertex Pharmaceuticals. This program is being conducted within the Therapeutics Development Network (TDN).
Contact us about VX-121 >